Bristol-Myers Squibb Company (NYSE:BMY) delivered a profit and met Wall Street’s expectations, AND came up short on beating the revenue expectation. The revenue miss is a negative sign to shareholders seeking high growth out of the company. Shares are down 1.09%.

Results: Adjusted Earnings Per Share decreased 35.94% to $0.41 in the quarter versus EPS of $0.64 in the year-earlier quarter.

Revenue: Decreased 27.04% to $3.83 billion from the year-earlier quarter.

Actual vs. Wall St. Expectations: Bristol-Myers Squibb Company reported adjusted EPS income of $0.41 per share. By that measure, the company met the mean analyst estimate of $0.41. It missed the average revenue estimate of $3.88 billion.

Quoting Management: “The first quarter was a good start to an important year in which our focus will be on the growth of existing brands, the execution of new launches and the continued delivery of a diverse and sustainable pipeline,” said Lamberto Andreotti, chief executive officer, Bristol-Myers Squibb. “So far this year, we have launched Eliquis in several markets around the world, have begun working with AstraZeneca to bring Byetta and Bydureon to patients outside the U.S., and have been preparing for the presentation of key clinical data across our pipeline.”

Key Stats (on next page)…

Revenue decreased 8.59% from $4.19 billion in the previous quarter. EPS decreased 12.77% from $0.47 in the previous quarter.

Looking Forward: Analysts have a more negative outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has fallen from a profit of $0.46 to a profit $0.45. For the current year, the average estimate is a profit of $1.83, which is the same with that ninety days ago.